In addition to directly acting agonists, interfering with TLR2 dimerization has been shown to ameliorate DSS colitis through effects on monocyte activation (201) and to improve Pam3CSK4-induced hepatic inflammation (202). This evidence concerns the gene TLR2 and colitis.